Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Overview
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Source
Originally published at www.marketwatch.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.